Moderna COVID Vaccine Approved: FDA & Restricted Use
- the Food and Drug administration has given the green light to Moderna's updated COVID-19 vaccine, mNEXSPIKE, but with some limitations on its use.
- the primary target group for the COVID vaccine is adults 65 and older.
- COVID-19, caused by the SARS-CoV-2 virus, spreads through person-to-person contact, infecting the respiratory system.
The FDA has approved Moderna’s updated mNEXSPIKE COVID-19 vaccine, primarily for adults 65 and older and those at high risk, marking a important step in the ongoing battle against the virus. This new mRNA vaccine offers enhanced protection compared to its predecessor,according to recent studies. Designed to combat the Omicron JN.1 variant, mNEXSPIKE stimulates the immune system to produce protective antibodies.The CDC advises that individuals aged 12-64 wiht underlying conditions may also be eligible for the updated shot. Studies showed mNEXSPIKE performed better in tests. side effects are typical of vaccines. As News Directory 3 reports, this approval emphasizes the importance of vaccination, especially for vulnerable populations. Discover what’s next in the evolution of COVID-19 protection.
FDA OKs New Moderna COVID Vaccine, mNEXSPIKE
Updated June 4, 2025
the Food and Drug administration has given the green light to Moderna’s updated COVID-19 vaccine, mNEXSPIKE, but with some limitations on its use. This mRNA vaccine is designed for individuals who have previously received a COVID-19 shot.
the primary target group for the COVID vaccine is adults 65 and older. However, individuals between 12 and 64 may also receive the mNEXSPIKE shot if they have at least one medical condition that elevates their risk of severe illness from COVID-19, according to the Centers for Disease Control and Prevention.
COVID-19, caused by the SARS-CoV-2 virus, spreads through person-to-person contact, infecting the respiratory system. While some experiance mild symptoms, older adults and those with conditions like heart disease, diabetes, obesity, cancer, or COPD face a higher risk of severe complications. last year, COVID-19 led to over 47,000 deaths in the U.S., underscoring the importance of vaccination, especially for vulnerable populations.
Moderna reported that the FDA’s approval of mNEXSPIKE was based on a study of about 11,400 participants ages 12 and up. The study indicated that the new COVID vaccine performed and also, and in some cases better than, the original Moderna vaccine, Spikevax. Specifically, mNEXSPIKE demonstrated about 9.3% greater protection in those 12 and older, and 13.5% better results in adults 65 and older.
The mNEXSPIKE vaccine utilizes mRNA technology,instructing the body to identify key proteins that enable the virus to infect cells. This updated COVID vaccine is based on the Omicron JN.1 variant, stimulating the immune system to produce protective antibodies.
Common side effects may include pain, redness, or swelling at the injection site, swollen lymph nodes in the same arm, fatigue, headache, muscle or joint pain, chills, nausea, vomiting, and fever.
what’s next
health officials will monitor the rollout of the new COVID vaccine and continue to encourage eligible individuals to get vaccinated to protect themselves and others from severe illness.